AstraZeneca / Daiichi Sankyo (Enhertu partnership)

Stories

Trastuzumab pamirtecan shows modest benefit in HER2-low breast cancer Phase 3 trial

Developer of the approved rival Enhertu

BioNTech and DualityBio's Phase 3 breast cancer trial met its main goal, but the result is muted. Trastuzumab pamirtecan delayed tumor growth longer than chemotherapy in 541 patients with hormone receptor-positive, HER2-low metastatic breast cancer, a gain the companies call "statistically significant, yet modest."

Updated Yesterday